SCHEMBL20074876

SCHEMBL20074876

Cn1nc(-c2ccc(F)cc2)c(Cl)c1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 2/20 0.59
MAPK13 O15264 1/20 0.43
CSNK1D P48730 1/20 0.43
CSNK1E P49674 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
SLC34A1 Q06495 6/20 0.43
SRC P12931 5/20 0.43
BRAF P15056 5/20 0.43
KDR P35968 5/20 0.43
EGFR P00533 2/20 0.42
RIPK2 O43353 1/20 0.42
TNK2 Q07912 1/20 0.42
PTK6 Q13882 1/20 0.42
MINK1 Q8N4C8 1/20 0.42
PDE1A P54750 1/20 0.40
PDE1B Q01064 1/20 0.40
PDE7A Q13946 1/20 0.40
PDE1C Q14123 1/20 0.40
MAP4K4 O95819 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13858455 0.82 MAPT (0.51) SLC34A1KDRCSNK1A1ALDH1A1NPSR1
SCHEMBL20075444 0.81 MAPK14 (0.60) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL20075477 0.79 MAPK14 (0.59) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL14039836 0.78 MAPK14 (0.43) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL20075550 0.78 SLC34A1 (0.47) MAPK14MAPK13MAPK12MAPK11SLC34A1
SCHEMBL20074676 0.77 MAPK14 (0.56) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL20075475 0.77 MAPK14 (0.56) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL16200053 0.77 SLC34A1 (0.44) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL13738455 0.77 MAPT (0.45) MAPK14MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL20075418 0.76 MAPK14 (0.44) MAPK14MAPK13CSNK1DCSNK1EMAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065629-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-03-02 US disclosed
US-11208400-B2 Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-12-28 US disclosed
US-11208400-B2 Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-12-28 US disclosed
EP-3526212-B1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AG (DE) 2021-12-22 EP disclosed
EP-3526212-B1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AG (DE) 2021-12-22 EP disclosed
US-20200055842-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-02-20 US disclosed
US-20200055842-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2020-02-20 US disclosed
WO-2018069222-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11208400-B2 Substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof REN, ATP6V1B1, GLS MAPK14 3191/4885MAPK13 3301/4885CSNK1D 1272/4885
US-20200055842-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF REN, ATP6V1B1, GLS MAPK14 3191/4885MAPK13 3301/4885CSNK1D 1272/4885
US-20230065629-A1 SUBSTITUTED 6-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF REN, ATP6V1B1, GLS MAPK14 3191/4885MAPK13 3301/4885CSNK1D 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.